Colorectal Cancer – Krazati with or without Erbitux in Mutated KRAS G12C
Background Adagrasib, also called “Krazati”, is a tablet taken by mouth which inhibits KRAS G12C mutation. It has shown clinical activity in pretreated patients with
Cannabidiol oil failed to overcome palliative care in advanced cancer
Background The use of cannabis for therapeutic benefit has risen exponentially over the past few years with strong public belief in its benefit. This is
Gastric Cancer – Zolbetuximab Prolongs Survival
About Locally Advanced Unresectable Metastatic Gastric Cancer and Gastroesophageal Junction Cancer (GEJ) Gastric cancer is the fifth most diagnosed cancer worldwide. Signs and symptoms can
Sarcoma – Lenvima Plus Halaven in Advanced Disease
In Short This phase Ib/II study evaluated the efficacy and safety of Lenvima combined with Halaven in the treatment of patients with advanced leiomyosarcoma and
Glioblastoma – Radiotherapy Plus Temodar With Nimotuzumab
Background about Glioblastoma and the new drug Glioblastoma (GBM) has a poor prognosis, and patients with Epidermal Growth Factor Receptor (EGFR) amplification have an even
Colorectal Cancer – Vitamin C in RAS mutated patients
The Rational for Vitamin C in Colorectal Cancer The use of vitamin C in cancer treatment can be traced to more than 40 years ago.
Small Cell Lung Cancer – Seplulimab Prolongs Life
Background In this randomized clinical trial that included 585 patients with extensive-stage Small Cell Lung Cancer, SCLC, who had not previously received systemic therapy, Seplulimab
Renal Cell Cancer – Triplet Therapy Improves Outcomes
Background A significant period until disease progression was seen in patients with metastatic renal cell cancer (RCC) receiving the triplet combination of Cometriq plus Yervoy
Bladder Cancer – Padcev Plus Keytruda in 1st Line
BACKGROUND Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic bladder cancer. However, toxicity is substantial, responses are rarely durable, and
Breast Cancer – Lurbinectadin in BRCA patients
Background Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient (HRD) models and preliminary clinical activity in BRCA1/2
Glioblastoma, GBM – A New & Novel Option for Patients
Background – Glioblastoma and CV-01 Glioblastoma is a diffuse, infiltrative disease with tumor cells invading far beyond the borders of the visible tumor. The diffuse
